Nerviano Medical Sciences S.r.l. Announces a Poster Presentation on NMS-03602173 at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

NERVIANO, 25 October 2022 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will be reported in a poster presentation by Dr. Paola Magnaghi at the upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2022) which will be held October 26-28, 2022 at the CCIB in Barcelona.

Details of the upcoming presentation are as follows:

Title: NMS-173, a potent, covalent second generation IDH1/IDH2 inhibitor
Presenter: Paola Magnaghi, Biomolecular Engineering Lab Head, NMS Srl
Poster #: 48
Session: Molecular Targeted Agents 1
Session Date/Time: Wednesday, 26 October 2022, All day
Location: Exhibition Hall

About NMS-03602173 (NMS-173)

NMS-173 is a second generation potent, covalent, selective, and orally available investigational new drug for the treatment of cancer patients with mutated IDH1 or IDH2. IDH1 and IDH2 mutations confer to these enzymes a neomorphic activity promoting the conversion of α-KG into 2-HG, an oncometabolite that induces a global epigenetic rewiring, leading to de-differentiation, stemness and tumorigenesis. NMS-173 potently inhibits mutant IDH1 and IDH2 thus resulting in the abrogation of 2-HG production in a variety of cells and in a number of in vivo mouse models including IDH mutant cholangiocarcinoma, glioma and AML models, with significant tumor growth inhibition and anti-tumor efficacy superior to FDA approved first generation inhibitors. Due to its covalent MOA, NMS-173 has high potential of sustained clinical responses compared to FDA approved drugs and can also potentially overcome resistance mechanisms to first generation IDH inhibitors. Notably, NMS-173 has received authorization to start phase I clinical studies in US and Europe in patients with IDH1 or IDH2 mutated solid tumors including low grade glioma.

About Nerviano Medical Sciences

Nerviano Medical Sciences S.r.l. (NMS Srl) is focused on discovery and clinical development of small-molecule new chemical entities (NCEs) for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs originating from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in-house and with partners.
NMS Srl combines the flexibility of a biotech with the quality of a big pharma. Our experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing).

A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.

About NMS Group

NMS Group is the largest oncological R&D company in Italy. More than half of our 400 employees are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group’s innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen anti-cancer projects, and four of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug products supporting clinical developments and commercialization.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it